IP Library › Granted Patent US 11,047,855
Granted Patent B2
US 11,047,855 · App. 15/555,258 · Granted Jun 29, 2021

Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens

Inventors: Rachel Sorek (Zafaria, IL); Keren Jakobi (Reut-Maccabim, IL); Pennina Safer (Rechovot, IL); Anat Reiner-Benaim (Binyamina, IL); Irun R. Cohen (Rehovot, IL)
Assignees: IMMUNARRAY LTD.; YEDA RESEARCH AND DEVELOPMENT CO. LTD.
G01N33/564G01N33/6854G01N2800/104G16B40/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,047,855
App. No.
15/555,258
Granted
Jun 29, 2021
Kind
B2
Abstract

Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, provided is a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.

Claims (12)

1. A method of detecting the levels of:

IgG antibodies reactive to ssDNA, IgG antibodies reactive to U1 snRNP, and IgG antibodies reactive to Sm; and

IgM antibodies reactive to Histone III-S, IgM antibodies reactive to U1 snRNP, and IgM antibodies reactive to an oligonucleotide antigen of the nucleic acid sequence TTA GGG TTA GGG TTA GGG TTA GGG (SEQ ID NO: 6, Oligo21),

in a sample of a subject having or suspected of having systemic lupus erythematosus (SLE), the method comprising:

(i) obtaining a serum, plasma, or blood sample from the subject;

(ii) exposing antibodies in the sample to ssDNA, Sm, Histone III-S, U1 snRNP, and Oligo21; and

(iii) detecting in the sample the levels of:

IgG antibodies reactive to ssDNA, IgG antibodies reactive to U1 snRNP and IgG antibodies reactive to Sm; and

IgM antibodies reactive to Histone III-S, IgM antibodies reactive to U1 snRNP and IgM antibodies reactive to Oligo21,

by quantifying the amount of antigen-antibody complex formed for each antigen, wherein the amount of antigen-antibody complex is indicative of the level of each respective antibody in said sample.

2. The method of claim 1 , wherein said sample is a serum sample.

3. The method of claim 1 , wherein the antigens are provided in the form of an antigen array, or an antigen chip.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: IMMUNARRAY LTD.
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 057130/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: COHEN, IRUN R.
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 052836/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2017
From: SOREK, RACHEL; JAKOBI, KEREN; SAFER, PENNINA; REINER-BENAIM, ANAT
To: IMMUNARRAY LTD.
Reel/Frame 043472/0239 →
Continuity (4)
Provisional Application 62126616 · Mar 1, 2015
Provisional Application 62181231 · Jun 18, 2015
Provisional Application 62249284 · Nov 1, 2015
Related Publication 20180238873A1 · Aug 23, 2018